Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

1.

Evaluating new cardiovascular risk factors for risk stratification.

Stern RH.

J Clin Hypertens (Greenwich). 2008 Jun;10(6):485-8. No abstract available.

PMID:
18550940
[PubMed - indexed for MEDLINE]
2.

[Role of biomarkers for risk stratification in the prevention of cardiovascular diseases].

Sinning C, Keller T, Blankenberg S.

Dtsch Med Wochenschr. 2009 Oct;134(40):2019-22. doi: 10.1055/s-0029-1237551. Epub 2009 Sep 23. Review. German. No abstract available.

PMID:
19777420
[PubMed - indexed for MEDLINE]
3.

Age as a modifiable risk factor for cardiovascular disease.

Sniderman AD, Furberg CD.

Lancet. 2008 May 3;371(9623):1547-9. doi: 10.1016/S0140-6736(08)60313-X. Epub 2008 Mar 5. Review. No abstract available.

PMID:
18321568
[PubMed - indexed for MEDLINE]
4.

[Inflammation and C-reactive protein in cardiovascular disease].

Munk PS, Larsen AI.

Tidsskr Nor Laegeforen. 2009 Jun 11;129(12):1221-4. doi: 10.4045/tidsskr.08.0011. Review. Norwegian.

PMID:
19521445
[PubMed - indexed for MEDLINE]
Free Article
5.

Overview of risk prediction models in cardiovascular disease research.

Cui J.

Ann Epidemiol. 2009 Oct;19(10):711-7. doi: 10.1016/j.annepidem.2009.05.005. Epub 2009 Jul 22. Review.

PMID:
19628409
[PubMed - indexed for MEDLINE]
6.

The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines.

Mora S, Musunuru K, Blumenthal RS.

Clin Chem. 2009 Feb;55(2):219-28. doi: 10.1373/clinchem.2008.109728. Epub 2008 Dec 18. Review.

PMID:
19095730
[PubMed - indexed for MEDLINE]
Free Article
7.

Cardiac biomarkers: myths, facts and future horizons.

Dotsenko O, Chackathayil J, Lip GY.

Expert Rev Mol Diagn. 2007 Nov;7(6):693-7. Review. No abstract available.

PMID:
18020898
[PubMed - indexed for MEDLINE]
8.

Candidate circulating biomarkers for the cardiovascular disease continuum.

Dotsenko O, Chackathayil J, Patel JV, Gill PS, Lip GY.

Curr Pharm Des. 2008;14(24):2445-61. Review.

PMID:
18781994
[PubMed - indexed for MEDLINE]
9.

The JUPITER trial: How will it change clinical practice?

Watson KE.

Rev Cardiovasc Med. 2009 Spring;10(2):91-6. Review.

PMID:
19593321
[PubMed - indexed for MEDLINE]
10.

Hope for the future: early recognition of increased cardiovascular risk in children and how to deal with it.

Masi S, Charakida M, Wang G, O'Neill F, Taddei S, Deanfield J.

Eur J Cardiovasc Prev Rehabil. 2009 Aug;16 Suppl 2:S61-4. doi: 10.1097/01.hjr.0000359240.52185.51. Review. No abstract available.

PMID:
19675441
[PubMed - indexed for MEDLINE]
11.

The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.

Kones R.

Ther Adv Cardiovasc Dis. 2009 Aug;3(4):309-15. doi: 10.1177/1753944709337056. Epub 2009 May 21. Review.

PMID:
19460829
[PubMed - indexed for MEDLINE]
12.

Updating the assessment of cardiac risk: beyond Framingham.

Borden WB, Davidson MH.

Rev Cardiovasc Med. 2009 Spring;10(2):63-71. Review.

PMID:
19593318
[PubMed - indexed for MEDLINE]
13.

Pregnancy-associated plasma protein-A (PAPP-A) and cardiovascular risk.

Consuegra-Sanchez L, Fredericks S, Kaski JC.

Atherosclerosis. 2009 Apr;203(2):346-52. doi: 10.1016/j.atherosclerosis.2008.07.042. Epub 2008 Aug 12. Review.

PMID:
18789800
[PubMed - indexed for MEDLINE]
14.

[Prognostic value and clinical effectiveness of high sensitivity C-reactive protein as a marker in primary prevention of major cardiac events].

Schwarzer R, Schnell-Inderst P, Grabein K, Göhler A, Stollenwerk B, Grandi N, Klauss V, Wasem J, Siebert U.

Z Evid Fortbild Qual Gesundhwes. 2009;103(6):319-29. Review. German.

PMID:
19839204
[PubMed - indexed for MEDLINE]
15.

Ethnicity and cardiovascular disease prevention: practical clinical considerations.

Jolly K, Gill P.

Curr Opin Cardiol. 2008 Sep;23(5):465-70. doi: 10.1097/HCO.0b013e32830a95c0. Review.

PMID:
18670258
[PubMed - indexed for MEDLINE]
16.

Cardiovascular protection for all individuals at high risk: evidence-based best practice.

Bakris G, Böhm M, Dagenais G, Diener HC, Fujita T, Gorelick P, Kjeldsen SE, Laakso M, Mancia G, Pitt B, Sharma A, Sleight P, Teo K, Unger T, Weber M, Williams B, Zannad F.

Clin Res Cardiol. 2008 Oct;97(10):713-25. doi: 10.1007/s00392-008-0713-2. Epub 2008 Aug 23. Review.

PMID:
18726243
[PubMed - indexed for MEDLINE]
17.

Cystatin C and cardiovascular risk.

Taglieri N, Koenig W, Kaski JC.

Clin Chem. 2009 Nov;55(11):1932-43. doi: 10.1373/clinchem.2009.128397. Epub 2009 Aug 27. Review.

PMID:
19713275
[PubMed - indexed for MEDLINE]
Free Article
18.

The use of surrogate vascular markers in youth at risk for premature cardiovascular disease.

McNeal CJ, Wilson DP, Christou D, Bush RL, Shepherd LG, Santiago J, Wu GY.

J Pediatr Endocrinol Metab. 2009 Mar;22(3):195-211. Review.

PMID:
19492575
[PubMed - indexed for MEDLINE]
19.

Should C-reactive protein be a target of therapy?

Oh J, Teoh H, Leiter LA.

Diabetes Care. 2011 May;34 Suppl 2:S155-60. doi: 10.2337/dc11-s211. Review. No abstract available.

PMID:
21525448
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Coagulation, genotypes and recurrent cardiovascular events: what further studies are required?

Lowe GD.

J Thromb Haemost. 2008 May;6(5):717-9. doi: 10.1111/j.1538-7836.2008.02947.x. Epub 2008 Mar 4. Review. No abstract available.

PMID:
18318688
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk